Who are Nimbex's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ecclock, Yupelri, Northera, Incruse Ellipta, Toviaz, Toviaz.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cisatracurium-besylate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Nimbex — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nimbex (Cisatracurium Besylate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nondepolarizing Neuromuscular Blocker. Area: Neuroscience.

marketed Nondepolarizing Neuromuscular Blocker Acetylcholine receptor Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Nimbex (Cisatracurium Besylate) — AbbVie. Nimbex works by blocking the action of acetylcholine at the neuromuscular junction, preventing muscle contraction.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nimbex TARGET	Cisatracurium Besylate	AbbVie	marketed	Nondepolarizing Neuromuscular Blocker	Acetylcholine receptor	1995-01-01
Ecclock	SOFPIRONIUM BROMIDE	Kaken Pharmaceutical	marketed		Muscarinic acetylcholine receptor M3	2024-01-01
Yupelri	REVEFENACIN	Mylan Ireland Ltd	marketed	Anticholinergic [EPC]	Muscarinic acetylcholine receptor M3	2018-01-01
Northera	DROXIDOPA	Lundbeck Na Ltd	marketed	Catecholamine	Muscarinic acetylcholine receptor M1	2014-01-01
Incruse Ellipta	UMECLIDINIUM	Glaxo Grp England	marketed	Anticholinergic	Muscarinic acetylcholine receptor M4	2013-01-01
Toviaz	FESOTERODINE	Pfizer	marketed	fesoterodine	Muscarinic acetylcholine receptor M2	2008-01-01
Toviaz	Fesoterodine Fumarate	Pfizer	marketed	fesoterodine	Muscarinic acetylcholine receptor M2	2008-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nondepolarizing Neuromuscular Blocker class)

AbbVie · 3 drugs in this class
· 1 drug in this class
Fresenius Kabi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nimbex — Competitive Intelligence Brief. https://druglandscape.com/ci/cisatracurium-besylate. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab